ArticleActa neurochirurgica2024
Risk score for early prognostication of aseptic bone flap necrosis.
Article in Acta neurochirurgica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bone flap resorption and its risk factors following autologous cranioplasty with bone tissue bank-stored grafts.Neurosurgical review · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeAseptic bone flap necrosis (ABFN) is a common complication of autologous cranioplasty that often requires reoperation. This study aimed to create a risk score for ABFN using relevant demographic, clinical, and laboratory markers.
methodsWe included all patients who underwent autologous cranioplasty after decompressive surgery between 2007 and 2019. We collected laboratory data, initial clinical diagnoses, and demographic parameters before autologous bone flap reimplantation. The significant predictors of ABFN identified in the final multivariate analysis were used to develop a risk score.
resultsOf the 412 patients who underwent craniectomy, 58 (14%, 32 females: 55.2%) developed ABFN. The following independent predictors of ABFN were included in the risk score (0-7 points): craniectomy due to trauma or hemorrhagic stroke (2 points), younger age (< 40 years, 2 points), cranioplasty timing (> 95 days post-craniectomy, 1 point), glutamate-pyruvate transferase < 18 U/L (1 point), and serum creatinine level < 0.815 mg/dL (1 point). The ABFN rates in patients with scores of 0-2, 3-4, and 5-7 points were 4.2%, 16.1%, and 34.6%, respectively. The risk score demonstrated moderate diagnostic accuracy for predicting ABFN, with an area under the curve of 0.739.
conclusionThe proposed risk score may help in early identification of individuals prone to ABFN. These data suggest that future studies should investigate the significance of metabolic syndromes related to ABFN occurrence. Understanding the potential impact of metabolic factors on ABFN can enhance risk assessment and targeted preventive measures for patients undergoing cranioplasty procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.